Education
About Us
Working with TipRanks
Follow Us
Cibus (CBUS)
NASDAQ:CBUS
CBUS Stock Chart & Stats
$1.44
-$0.23(-7.99%)
At close: 4:00 PM EST
$1.44
-$0.23(-7.99%)
Day’s Range― - ―
52-Week Range$1.20 - $6.10
Previous CloseN/A
Volume64.89K
Average Volume (3M)600.30K
Market Cap
$90.06M
Enterprise Value$275.23M
Total Cash (Recent Filing)$36.46M
Total Debt (Recent Filing)$35.42M
Price to Earnings (P/E)―
Beta3.28
Next Earnings
Nov 06, 2025EPS Estimate
-0.44Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.61
Shares Outstanding52,540,527
10 Day Avg. Volume1,378,741
30 Day Avg. Volume600,304
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap3.06
Enterprise Value/Revenue56.80
Enterprise Value/Gross Profit56.80
Enterprise Value/Ebitda-1.05
Forecast
1Y Price Target
$20.00Price Target Upside1288.89% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Bulls Say, Bears Say
Bulls Say
Cost ManagementCibus reported a reduction in operating expenses driven by management’s cost reduction efforts, which is part of a restructuring initiative aimed at focusing on core projects.
Revenue GenerationManagement expects the commercialization of Cibus' sustainable ingredients and biofragrance products to generate significant revenues, with expectations of material expansion in the future.
Strategic PartnershipsThe company expects to generate initial revenues from the biofragrance partnership with a large consumer packaged goods partner, indicating potential new income streams.
Bears Say
Financial ChallengesCibus announced a quarterly net loss, highlighting ongoing financial challenges despite improvements.
Investor SentimentMaintaining the timeline for their core gene-edited trait and sustainable ingredient opportunities is crucial, as delays could impact investor sentiment.
Cibus News
CBUS FAQ
What was Cibus’s price range in the past 12 months?
Cibus lowest stock price was $1.20 and its highest was $6.10 in the past 12 months.
What is Cibus’s market cap?
Cibus’s market cap is $90.06M.
When is Cibus’s upcoming earnings report date?
Cibus’s upcoming earnings report date is Nov 06, 2025 which is in 13 days.
How were Cibus’s earnings last quarter?
Cibus released its earnings results on Aug 14, 2025. The company reported -$0.61 earnings per share for the quarter, missing the consensus estimate of -$0.602 by -$0.008.
Is Cibus overvalued?
According to Wall Street analysts Cibus’s price is currently Undervalued.
Does Cibus pay dividends?
Cibus does not currently pay dividends.
What is Cibus’s EPS estimate?
Cibus’s EPS estimate is -0.44.
How many shares outstanding does Cibus have?
Cibus has 52,540,527 shares outstanding.
What happened to Cibus’s price movement after its last earnings report?
Cibus reported an EPS of -$0.61 in its last earnings report, missing expectations of -$0.602. Following the earnings report the stock price went down -4.082%.
Which hedge fund is a major shareholder of Cibus?
Currently, no hedge funds are holding shares in CBUS
Cibus Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$20.00 (1288.89% Upside)
$20.00 (1288.89% Upside)
Hedge Fund Trend
Decreased
By 22.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 21.6%
Last 30 Days ▲ 21.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-53.76%
12-Months-Change
Fundamentals
Return on Equity
-160.72%
Trailing 12-Months
Asset Growth
-37.44%
Trailing 12-Months
Company Description
Cibus
Cibus (CBUS) is a biotechnology company specializing in the development of innovative agricultural solutions, particularly focusing on crop protection and enhancement through its proprietary gene-editing technology. The company operates primarily in the agricultural sector, offering products that aim to improve crop yields, enhance resistance to pests and diseases, and reduce the need for chemical pesticides. Cibus is committed to sustainable agriculture practices and works to provide farmers with tools that are both effective and environmentally friendly.
CBUS Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant progress in the commercialization of rice herbicide traits and biofragrance products, alongside positive regulatory developments. However, challenges include a delay in the EU regulatory process and a notable net loss. The company's strategic focus on cost reduction and capital allocation is aimed at managing cash usage effectively.View all CBUS earnings summariesCBUS Stock 12 Month Forecast
Average Price Target
$20.00
▲(1288.89% Upside)
Technical Analysis
CervoMed
―
X4 Pharmaceuticals
―
ABVC BioPharma
―
Repare Therapeutics
―
OKYO Pharma Limited Sponsored ADR
―
Ownership Overview
32.65% Insiders
6.76% Mutual Funds
4.88% Other Institutional Investors
54.16% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---